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Background: The RAS/MAPK signaling pathway can regulate gene expression by phosphorylating and altering the
function of some, but not all, ETS transcription factors. ETS family transcription factors bind similar DNA sequences and
can compete for genomic binding sites. However, MAPK regulation varies across the ETS family. Therefore, changing
the ETS factor bound to a cis-regulatory element can alter MAPK regulation of gene expression. To understand RAS/
MAPK regulated gene expression programs, comprehensive knowledge of the ETS family members that are MAPK
targets and relative MAPK targeting efficiency across the family is needed.
Results: An in vitro kinase assay was used to rank-order 27 human ETS family transcription factors based on
phosphorylation by ERK2, JNK1, and p38α. Many novel MAPK targets and specificities were identified within the
ETS family, including the identification of the prostate cancer oncoprotein ERG as a specific target of ERK2. ERK2
phosphorylation of ERG S215 required a DEF docking domain and was necessary for ERG to activate transcription of cell
migration genes and promote prostate cell migration. The ability of ERK2 to bind ERG with higher affinity than ETS1
provided a potential molecular explanation for why ERG overexpression drives migration of prostate cells with low
levels of RAS/ERK signaling, while ETS1 has a similar function only when RAS/ERK signaling is high.
Conclusions: The rank ordering of ETS transcription factors as MAPK targets provides an important resource for
understanding ETS proteins as mediators of MAPK signaling. This is emphasized by the difference in rank order of ERG
and ETS1, which allows these factors to have distinct roles based on the level of RAS/ERK signaling present in the cell.
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migrationIntroduction
Most transcription factors can be grouped into families
based on common DNA binding domains [1] leading to
similar DNA sequence preferences [2]. Through binding
site competition, changes in the level of one family
member can alter the relative portion of time each other
family member occupies a specific location in the gen-
ome. If family members have distinct transactivation
functions, this competition will alter the expression of
target genes. Furthermore, if distinct signaling pathways* Correspondence: pchollen@indiana.edu
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unless otherwise stated.regulate the transactivation function of different family
members, this switch can change the signaling require-
ments for target gene expression. Predicting how these
changes will alter gene expression requires direct func-
tional comparisons.
There are 28 genes encoding ETS family transcription
factors in humans. All ETS factors have a winged helix-
turn-helix DNA binding domain that allows monomeric
binding to the sequence GGA(A/T) [3]. However, ETS
factors vary considerably outside of the DNA binding
domain, allowing diverse trans-regulatory roles. ETS
family transcription factors are extensively co-expressed,
with at least 15 members expressed in any cell type [4].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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types have identified competition for some target se-
quences between family members [5,6]. A variety of ETS
transcription factors have been identified as mediators of
RAS/MAPK signaling [7]. Phosphorylation of ETS pro-
teins by distinct classes of MAPK, including ERK, JNK,
and p38, can alter transcriptional functions by various
mechanisms including changing DNA affinity [8], in-
creasing co-activator recruitment or activity [9,10], or al-
tering subcellular localization [11,12].
Knowing that an ETS factor is a MAPK target is im-
portant for understanding regulatory mechanisms. For
example, we have recently demonstrated that competi-
tion between ETS proteins for a RAS-response element
consisting of neighboring ETS and AP-1 binding sites al-
ters cancer cell migration. The ubiquitously expressed
ETS protein ETS1 binds ETS/AP-1 sequences in the en-
hancers of cell migration genes [13]. ETS1 is phosphory-
lated by ERK when ERK signaling is high, and this
increases the transactivation potential of ETS1 and in-
creases expression of cell migration-promoting genes.
However, in about one-half of prostate tumors, the ETS
protein ERG is over-expressed due to a chromosomal
rearrangement [14]. This results in ERG replacing
ETS1 at ETS/AP-1 sequences and activating expression
of these genes in cells with high levels of PI3K/AKT sig-
naling, but low levels of ERK signaling [15,16]. There-
fore, the replacement of ETS1 with ERG alters the
signaling requirement for activation of this gene ex-
pression program.
Despite the importance of MAPK signaling in the ETS
family, it is unknown how many of the 28 human ETS
family members can respond to this signaling pathway.
Multiple studies have identified individual ETS proteins
as a MAPK targets [7]. However, whether or not these
particular ETS factors are strong or weak targets com-
pared to all of the other family members that are present
in the same cell remains unknown. Here we present the
first comprehensive comparison of MAPK targeting
within the ETS family. 27 full-length human ETS pro-
teins were purified, and in vitro kinase assays tested
phosphorylation specificity for three MAPKs (ERK2,
JNK1, and p38α). We provide a rank-ordered compari-
son of MAPK specificity across the ETS family, confirm
known targets and identify many new targets. One strik-
ing new observation is the phosphorylation of ERG by
ERK. We found that ERK targets S215 of ERG both
in vitro and in vivo by interacting with a neighboring
DEF domain. This phosphorylation event was critical for
the ability of ERG to increase cell migration of prostate
epithelial cells. Furthermore, using biochemical methods
we determined the affinity of ERK2 for ERG is greater
than that for ETS1. This relatively higher affinity corre-
lates with the ability of ERG but not ETS1 to function incells with low levels of ERK signaling. This example
demonstrates the utility of direct comparisons of kinase
targeting within a transcription factor family.
Results
Comparing MAPK phosphorylation of all human ETS
factors
To compare ETS family transcription factors, full-length
cDNAs of each human ETS gene were expressed in E.
coli with a 6x Histidine tag on the N-terminus. For ETS
genes that express multiple transcripts, we chose ver-
sions commonly described in the literature, and biased
our selections towards longer versions to include as
many potential MAPK target sequences as possible. The
transcripts and primer sequences used are in (Additional
file 1: Table S1). In sum, 27 ETS proteins were purified
from inclusion bodies, solubilized in 5 M urea and then
re-folded (Figure 1, top). 25 ETS proteins were soluble
in wild-type form after re-folding. Previous studies had
reported that the ETS protein ETV6 (TEL) can polymerize
through a PNT domain and is insoluble when purified
[17,18]. Similarly, the related ETS protein ETV7 (TEL2) is
also known to self-associate [19] and, thus, is likely to be
insoluble. For this reason, we expressed and purified hu-
man ETV6 with an A93D mutation, which in murine
ETV6 disrupts polymerization and results in a soluble
protein [17]. An analogous mutation (A86D) in human
ETV7 was also utilized. Both mutant proteins were soluble
and used in place of ETV6 and ETV7 in this study. For all
27 ETS proteins, DNA binding activity in an EMSA con-
firmed proper folding (Additional file 2: Figure S1).
A 28th ETS family member named ETV3L is predicted
from genomic sequence, but has not been characterized.
Unlike the other 27 ETS family members, we were not
able to amplify ETV3L cDNA, nor express ETV3L pro-
tein from a synthetic construct. For these reasons, it is
unclear if ETV3L represents an expressed protein-
coding gene in humans and we focused on the other 27
ETS family members.
Each ETS transcription factor was used in an in vitro
kinase assay with radiolabeled ATP and purified ERK2,
JNK1, or p38α kinase (Figure 1). Radiolabel density for
the band representing each full-length ETS factor was
normalized to coomassie stain density of the same band
in the same gel (Additional file 3: Figure S2), and then
normalized to the ratio for the ETS1 protein, which was
included as a loading control on every gel. This normal-
ized score was then used to rank-order each ETS protein
based on the extent of in vitro phosphorylation by each
MAPK (Tables 1, 2 and 3). We avoid an arbitrary cut-off
to report any ETS protein as phosphorylated or not, be-
cause such a conclusion would vary based on the activ-
ity and local concentration of the kinase in vivo. A
comparison with previous reports identifying in vitro
Figure 1 MAPK specificity across the ETS family. Coomassie staining of purified ETS proteins (top) or autoradiograph of 32P labeled ETS
proteins by ERK2, JNK1, or P38α kinase.
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families shows that these findings cluster near the top
of our rank order, particularly in the case of the well-
studied ERK-ETS interactions (Tables 1, 2 and 3).Role of MAPK interaction motifs in ETS family specificity
For many of the ETS proteins, ERK2, JNK1 and p38α
produced very similar phosphorylation signals (Figure 1),
reflected in similarities in the rank order (Tables 1, 2
and 3). MAPKs can bind target proteins by docking to D
or DEF domains [36] and then phosphorylating neigh-
boring serine or threonine residues, within consensus
PX(TP/SP) motifs, or sometimes within TP or SP motifs
that lack a preceding proline. To identify motifs corre-
sponding to phosphorylation by all three MAPKs, in
Table 4 we sorted the ETS proteins by ascending mean
rank order for all three MAPKs, and listed the number
of predicted MAPK interaction domains and potential
target residues. This analysis identified a strong correl-
ation between a high level of phosphorylation by all
three kinases and the number of PX(TP/SP) motifs in
the protein. For example, seven ETS proteins have more
than one PX(TP/SP) motif, and these include all of the
top five in Table 4. Eleven ETS proteins lack a PX(TP/
SP) motif, and these include nine of the bottom 10 in
Table 4. Therefore, PX(TP/SP) motifs likely target phos-
phorylation by all three MAPKs, and a higher number ofthese motifs leads to more phosphorylation sites and a
higher signal in the assay.
While many ETS proteins were phosphorylated in a
similar manner by each MAPK, there were several inter-
esting exceptions. For example, ELF2 and ETV6 were
more phosphorylated by p38α than by ERK2 or JNK1
(Figure 1). The D domain is considered an interaction
domain for all three MAPK classes. However, p38 ki-
nases have additional acidic residues in their docking re-
gions [37] and the introduction of basic residues into
target proteins can promote p38 specificity [38]. There-
fore, we searched for basic residues in the D domains of
the ETS proteins that might interact with p38α. One
part of the D domain, called the LXL motif, consists of
two hydrophobic amino acids surrounding a variable
residue. The D-Finder algorithm [39] was used to iden-
tify 60 D domains in the 27 ETS protein sequences
(Additional file 4: Table S2). Of these 60, only two had a
basic arginine residue in the central, variable position of
the LXL motif (LRL). These two D domains were in
ELF2 and ETV6, the same two ETS factors with p38α
specificity. Therefore an LRL motif may contribute to
p38 specific kinase targeting.
Another group of ETS proteins were more efficiently
phosphorylated by ERK2 than by JNK1 or p38α. These
included ETS1 and ETS2, which had slight specificity,
and ELK3 and ERG, which showed strong specificity for
ERK2 (Figure 1). Unlike the D domain, the DEF domain
Table 1 ERK2 kinase specificity in the ETS family
Protein Score Previous report
ELK1 22.7 Yang et al. [20]
ETV5 9.0 Janknecht et al. [21]
ERF 8.9 Le Gallic et al. [22]
ELK4 8.4 Strahl et al. [23]
ETV3 6.9 Carlson et al. [8]
ERG 2.0
FEV 1.3
ELK3 1.2 Ducret et al. [24]
SPIB 1.2 Mao et al. [25]
ETS1 1.0 Yang et al. [26]
ETS2 1.0 Yang et al. [26]
ETV7 0.8
ETV4 0.8 O’Hagan et al. [27]
ETV1 0.8 Janknecht [28]
ETV6 0.7 Maki et al. [29]
ELF4 0.7











The phosphorylation score is the ratio of radiolabel to total protein normalized
to ETS1. The third column references a previous report of in vitro
phosphorylation by any member of the ERK MAPK family, if applicable.
Table 2 JNK1 kinase specificity in the ETS family
Protein Score Previous report







SPIB 1.7 Mao et al. [25]
ELF2 1.7
ETV4 1.5
ETS1 1.0 Paumelle et al. [31]
ETS2 1.0 Fowles et al. [32]
ETV6 0.9
SPDEF 0.6
SPI1 0.6 Mao et al. [25]
ELK3 0.5 Ducret et al. [24]
ELF4 0.5
ETV1 0.4 Janknecht [28]
ELF3 0.3








Scoring and previous reports for JNK, as in Table 1.
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[40,41]. The consensus DEF domain sequence (FXFP)
occurs in only seven ETS proteins (Table 4). Among
these are four ETS proteins with multiple PX(TP/SP)
motifs, where an ERK-specific phosphorylation event
would be difficult to detect due to less-specific phos-
phorylation at other sites. Of the twenty ETS proteins
with zero or one PX(TP/SP) motif, only three had an
FXFP sequence, and two of these three were ELK3 and
ERG, the proteins where we observed strong ERK2 spe-
cificity. Therefore, the DEF domain correlates with ERK
specificity in the ETS family.
ERK phosphorylates ERG S215 via a DEF domain
The results provided in Figure 1 and Tables 1, 2 and 3
allow comparison of relative phosphorylation efficiency
between ETS family members in vitro. To test whetherthese results can provide important information regard-
ing differences in in vivo ETS functions, we focused on
the ability of ERK2 to phosphorylate ERG. ERG is the
ETS protein with the highest level of ERK2 phosphoryl-
ation that had not been previously reported in the litera-
ture (Table 1). To identify the ERK2 target residue,
purified ERG was phosphorylated by ERK in vitro, and
analyzed by mass spectrometry. Three potential phos-
phorylation sites were identified (Figure 2A and B).
These were S215, S276, and S96. To test the require-
ment of these residues for in vitro phosphorylation by
ERK2, ERG proteins were purified with alanine substitu-
tions at each of these residues, plus two additional
nearby TP or SP sequences, T180 and S81. Of these five
substitutions, only S215A completely ablated the phos-
phorylation signal (Figure 2C, left panels), indicating that
S215 is the major ERK2 phosphorylation site. The S96A
mutation reduced the signal, indicating a potential
Table 3 p38α kinase specificity in the ETS family
Protein Score Previous report
ETV3 31.9
ELK1 23.4 Yang et al. [20]
ELF2 13.3
ETV7 12.0




ERF 4.9 Polychronopoulos et al. [35]






ETS1 1.0 Paumelle et al. [31]
SPI1 0.5










Scoring and previous reports for p38, as in Table 1.
Table 4 Presence of MAPK interaction motifs in the ETS
family
ETS Mean Rank D Domain FXF FXFP PX(S/T)P SP/TP
ELK1 1.3 2 1 1 3 14
ETV3 2.7 4 3 1 2 12
ELK4 4.3 1 1 1 3 18
ETV5 5.0 3 0 0 3 6
ERF 6.0 2 5 2 7 18
ETV7 6.3 2 1 0 1 7
FEV 6.7 1 1 0 1 2
ELF2 9.7 4 0 0 1 16
SPIB 9.7 0 1 0 1 3
ETV6 11.7 3 1 0 2 16
ETV4 12.0 2 0 0 1 7
ETS1 12.3 3 0 0 0 4
ETS2 12.3 2 0 0 0 5
ETV1 14.0 3 1 0 2 6
ELK3 14.3 4 1 1 1 15
ELF4 14.7 4 0 0 1 8
SPDEF 16.3 2 0 0 1 8
ERG 16.3 2 1 1 0 10
SPI1 19.3 1 1 0 0 3
GABPA 20.3 2 0 0 0 2
ELF3 21.0 0 1 0 0 2
FLI1 21.0 2 0 0 0 4
ELF1 21.0 6 1 0 1 12
ELF5 24.0 0 0 0 0 1
EHF 24.7 2 1 0 0 1
ETV2 25.0 2 1 1 0 3
SPIC 26.0 1 1 0 0 2
ETS proteins are listed by the mean ranking for ERK2, JNK1, and p38α from
Tables 1, 2 and 3. The number of indicated motifs is listed. Sequence of D
domains is detailed in (Additional file 4: Table S2).
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Significantly, S215 represents the nearest SP or TP se-
quence to the DEF domain found in ERG (Figure 2B). To
test the role of the DEF domain, ERG was purified with a
mutation in this domain (FIFP to AAAP). An in vitro phos-
phorylation assay showed that both S215 and DEF domain
mutations ablate the ability of ERK2 to phosphorylate ERG
(Figure 2C, center panels), indicating that S215 is targeted
by ERK2 binding to the DEF domain in vitro. In cloning
ERG (isoform 1), we also cloned an alternatively spliced
version of ERG lacking Exon 9 (isoform 10, ERGi10).
ERGi10 lacks 24 amino acids including the DEF domain
(Figure 2B), but retains S215. Purified ERGi10 was not
phosphorylated, consistent with a requirement for the DEF
domain within Exon 9 (Figure 2C, right panels).
A previous mass spectrometry analysis of ERG immuno-
precipitated from prostate cancer cells with a TMPRSS2/
ERG fusion, identified S215 phosphorylation [42], indicatingthat this modification can occur in vivo. To measure S215
phosphorylation in vivo, a phospho-specific antibody to
ERG S215p was raised (pERG antibody). This antibody de-
tected purified ERG protein only after it was phosphory-
lated by ERK2 (Figure 3A). The RWPE-ERG cell line was
then used to identify ERG phosphorylation in vivo. RWPE1
cells are derived from normal prostate epithelia and do not
express ERG. Stable expression of 3xFlag tagged ERG via a
retroviral vector creates RWPE-ERG cells. ERG was immu-
noprecipitated from RWPE-ERG cells with the Flag anti-
body, then immunoblotted with the ERG and pERG
antibodies. The pERG antibody detected a band the same
size as ERG, and this band disappeared when the extract
was treated with alkaline phosphatase, indicating that it de-
tected a phosphorylation site (Figure 3B). RWPE1 cells sta-
bly expressing ERG with S215A and AAAP mutations or
Figure 2 ERG is phosphorylated at S215 by ERK via an FXFP motif. (A) Mass spectrum of ERK2 phosphorylated ERG peptide fragment (ALQNS*PR)
identifying phosphorylation of S215. (B) Schematic representation of ERG and ERGi10 protein isoforms showing possible ERK binding motifs (D and DEF
domains, indicated as boxes) and potential phosphorylation sites (TP and SP sequences, indicated with lines). Serine and threonine residues interrogated in
(C) are annotated. Dashed lines define the region coded by exon 9. (C) In vitro kinase assays, as in Figure 1, show ERK2 phosphorylation of the indicated
proteins. Note that bovine serum albumin (BSA) was included in the kinase buffer in the left panels, but had no effect on the specificity of the assay
(compare to center panel), and was therefore not used in other kinase assays.
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mutant ERG proteins and ERGi10 were expressed at similar
levels to ERG, but were not detected by the pERG antibody
(Figure 3C to E). These findings indicate that the pERG
antibody is specific for ERG S215 phosphorylation, and the
ERG DEF domain is required for S215 phosphorylation
in vivo.
To identify the signaling pathway that results in ERG
S215 phosphorylation in vivo, RWPE-ERG cells were
treated with eight different kinase or signaling pathway
inhibitors. The only inhibitor to reduce S215 phosphor-
ylation was the MEK inhibitor (Figure 3F). MEK phos-
phorylation of ERK is necessary for ERK kinase function,
so these results are consistent with ERK being the kinase
that phosphorylates ERG S215 in vivo.
S215 phosphorylation is necessary for ERG to promote
prostate cell migration
ERG is not normally expressed in prostate cells. However,
in 50% of prostate cancers, a chromosomal rearrangementof the ERG gene results in high ERG expression [14]. ERG
expression in prostate cells has been shown to increase
cellular migration and invasion [15,43]. In a transwell mi-
gration assay, ERG over-expression increased RWPE1 cell
migration, but a mutation of the ERK phosphorylation site
(S215A) completely abolished this function (Figure 4A to
C). Similarly, mutation of the DEF domain sequence (FIFP
to AAAP) abolished the ability of ERG to drive cell migra-
tion (Figure 4D to F). Likewise, ERGi10, which lacks S215
phosphorylation (Figure 3E) could not induce RWPE cell
migration (Figure 4G to I).
As a transcription factor, the role of ERG in cell mi-
gration is likely due to regulation of target gene expres-
sion. To test the role of S215 phosphorylation in ERG
transcriptional function, we compared the levels of
PIK3AP1 and ARHGAP29, two ERG target genes [15]
with known cell migration and oncogenic functions
[44,45]. Both genes were activated about three-fold by
ERG expression in RWPE1 cells, but neither were acti-
vated by an ERG S215A mutant (Figure 4J). Therefore
Figure 3 ERG is phosphorylated at S215 by the RAS/MEK/ERK pathway in prostate epithelial cells. (A) Immunoblot of purified ERG protein
with phospho-S215 pERG antibody after phosphorylation by ERK, or mock treatment. (B) Immunoblot with pERG or total ERG antibodies of whole cell
extract, or protein immunoprecipitated with Flag antibody from Flag-ERG expressing RWPE1 cells. Immunoprecipitates were treated with
alkaline phosphatase as indicated. (C, D, E) Immunoblots as in (B), but from RWPE1 cells stably expressing the indicated ERG construct. (F)
Immunoblots as in (B), but from cells treated with the indicated inhibitors, or DMSO as a negative control.
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ERG target genes in prostate cells.
The inability of ERG S215 to activate target genes could
be due to a defect in subcellular localization, genomic occu-
pancy, or transactivation function. To test localization, nu-
clear and cytoplasmic fractions of RWPE cells expressing
ERG or ERG-S215A were immunoblotted. ERG was found
to be in both the cytoplasm and the nucleus, and this distri-
bution was unchanged in ERG-S215A (Figure 4K).
Chromatin immunoprecipitation of ERG or ERG-S215A
revealed a trend of reduced occupancy for ERG-S215A,
compared to ERG, at three target loci (Figure 4L). This
finding indicates that S215 phosphorylation may play a
role in the interaction of ERG with chromatin.A high affinity ERK-ERG interaction allows ERG function
when there is low ERK signaling
We have previously shown that both ERG and the ubi-
quitously expressed ETS protein, ETS1, can bind the
ETS/AP-1 RAS-response element in the enhancers of
cell migration genes, including PIK3AP1 and ARH-
GAP29, but have distinct roles in cell migration depend-
ing on RAS/ERK signaling status [13,15]. In RWPE1
prostate cells, ERG, and not ETS1, promotes cell migra-
tion (Figure 5A). However, the over-expression of KRAS
in RWPE1 cells (RWPE-KRAS, also known as RWPE2),
allows ETS1 and not ERG to promote cell migration
(Figure 5B). Table 1 indicates that ERG is a more robust
ERK target than ETS1. If this difference allows ERG to
Figure 4 ERG requires S215 and the FXFP motif to promote prostate cell migration and activate target genes. (A, D, G) Flag Immunoblots of
RWPE1 cells stably expressing the indicated Flag-ERG proteins. (B, E, H) Representative images of transwell migration assays in the given cell
lines (C, F, I) Quantification of transwell assays shows relative number of cells migrated compared to empty vector as the mean and SEM of at
least three biological replicates. (J) qRT-PCR measured relative mRNA levels of migration related genes in ERG expressing RWPE1 cells compared to
those expressing vector only. Mean and SEM of three replicates. (K) Nuclear (Nu) and cytoplasmic (Cy) fractions of RWPE1 cells expressing the indicated
Flag-tagged proteins were immunoblotted with the indicated antibodies. Histone H3 and tubulin control for proper fractionation. All lanes are from
the same exposure of the same blot, but extraneous lanes were removed at the vertical line. (L) Chromatin immunoprecipitation (ChIP) of ERG
or ERG-S215 at three target loci. Two biological replicates (R1 and R2) are shown. Enrichment is the ratio of the copy number of the target loci
to the mean copy number of two negative control loci in the same ChIP sample, as measured by quantitative PCR. All P values in this figure
by T-test (* < 0.01, ** < 0.005, *** < 0.001).
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while ETS1 can only function in cells with high levels
of pERK (RWPE-KRAS), it would explain the difference
in Figure 5A and B.
To more quantitatively assess ERK selectivity, we used
three concentrations of purified protein to compare
ERK2 phosphorylation of ERG and ETS1 (Figure 5C).
ETS1 is known to have two ERK phosphorylation sites
(T38 and S41) [46], while ERG has one (S215), or two(S96), so the radiolabel for pETS1 should be higher, or
equal to, that of pERG if the kinase targets both proteins
similarly. Despite this, quantification of the blot (Figure 5D)
indicates approximately three-fold higher phosphorylation
of ERG compared to ETS1. As a control, ETS2 was also
tested. Consistent with Table 1, there was no difference in
ERK2 phosphorylation of ETS1 and ETS2 (Figure 5D).
This higher selectivity could be due to ERK docking
with ERG with higher affinity than ETS1. To test this,
Figure 5 (See legend on next page.)
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Figure 5 ERK has higher affinity for ERG than ETS1 and ERG is phosphorylated in cells with lower pERK levels. (A, B) A transwell assay compared
cell migration of RWPE1 and RWPE-KRAS (RWPE2) cell lines over-expressing the indicated ETS protein compared to empty vector. Mean and SEM of three
biological replicates are shown. P-values (* < 0.01, ** < 0.005) by T-test. (C) Indicated amount of purified ETS1, ETS2 and ERG were phosphorylated in vitro
by ERK2 kinase. Coomassie staining indicates total protein and an autoradiograph, phosphorylation. (D) Quantification of radiolabel density in
(C) in arbitrary density units. (E) The binding of fluorescently labeled ERK2 to varying concentrations of ERG or ETS1 by microscale thermophoresis
(MST). (F) Immunoblots with indicated antibodies of cell extracts or Flag-immunoprecipitate from cells stably over-expressing ERG in the presence of
the MEK inhibitor U0126, or over-expressed KRAS, as indicated. (G) Immunoblots as in F, but with cells stably over-expressing ETS1.
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using microscale thermophoresis (MST) (Figure 5E).
The affinity of ERK for ERG (KD = 0.23 μM) was eight
times higher than for ETS1 (KD = 1.79 μM), and this dif-
ference was statistically significant (P = 0.023, by T-test).
These in vitro data suggest that low levels of pERK
could phosphorylate ERG, but higher levels would be
required to phosphorylate ETS1. To test if this is true
in vivo, levels of pERG and pETS1 were compared in
the RWPE system. RWPE cells over-expressing ERG
(Figure 5F) or ETS1 (Figure 5G), had low levels of
pERK. Treatment with the MEK inhibitor U0126 fur-
ther reduced pERK levels, and over-expression of KRAS
increased pERK levels (Figure 5F and G). Phosphoryl-
ation of ETS1 was only observed in cells with high
levels of pERK (Figure 5G, RWPE-KRAS), consistent
with ETS1 promoting cell migration in only this cell
line (Figure 5B). In contrast, ERG was phosphorylated
in RWPE1 cells, and ERG phosphorylation did not in-
crease in RWPE-KRAS cells (Figure 5F), indicating that
low levels of pERK are sufficient for peak ERG phos-
phorylation in vivo. There was actually a small decrease
in ERG phosphorylation in RWPE-KRAS cells indicat-
ing the potential for additional feedback mechanisms
controlling this modification. These findings are con-
sistent with a model that due to a high-affinity ERK
interaction, ERG functions in prostate cells with low
level ERK signaling and ETS1 functions in prostate cells
with high ERK signaling. These results indicate that a
direct comparison of MAPK function between ETS
proteins, as shown in Figure 1, can inform in vivo
mechanisms.
Discussion
The ETS family DNA binding sequence (consensus
CCGGAAGT) occurs in multiple cis-regulatory motifs
that mediate the gene expression changes that occur after
mitogen signaling [47,48]. However, the size of the ETS
family has made it difficult to determine all of the ETS fac-
tors that could potentially activate or repress these genes.
Here we provide the relative specificity of MAPKs across
the ETS family of transcription factors. These data allow
predictions of changes in signaling response that could
occur when one bound ETS factor is replaced by another,
either due to changes in expression levels, subcellularlocalization, or DNA affinity. We provide one example of
the type of findings that can result from this dataset: The
novel, high-affinity interaction of ERK with ERG that pro-
vides a potential explanation for how ERG can promote
migration of prostate cells with low levels of RAS/ERK
signaling, but ETS1 cannot.
Comparing MAPK targeting of ETS factors provided
data consistent with previous studies (Tables 1, 2 and 3),
but also puts these studies into perspective within the
greater ETS family. The ternary complex factor (TCF)
subfamily of ETS factors including ELK1, ELK3 (NET),
and ELK4 (SAP1) are among the best-studied MAPK
targets [49]. These factors bind to serum-response ele-
ments due to a cooperative interaction with SRF and
mediate immediate early gene expression [50]. ELK1 is
phosphorylated at multiple sites by all three MAPK clas-
ses [20,51]. We found that ELK1 was, by far, the most
phosphorylated ETS protein by ERK2 and JNK1 in vitro,
and is the second most phosphorylated by p38α. ELK4
is known to be a better substrate for ERK and p38 ki-
nases [34], than for JNK [47], and our findings agreed
(Figure 1). ELK3 can also be a target for all three
MAPKs [24], but we found lower levels of phosphoryl-
ation compared to the other two TCFs. ELK3 also had
specificity for ERK2, likely due to a DEF domain. An-
other interesting finding involved ETV3, which has
been recently identified as a target of ERK2 [8]. We
found that ETV3 was indeed the fifth most phosphory-
lated ETS by ERK2 (Table 1). But ETV3 was also a very
strong JNK1 and p38α substrate, ranking second and
first, respectively, within the ETS family, indicating a
potential role for these pathways in ETV3 function. A
few ETS proteins previously reported as MAPK targets
showed very little phosphorylation in our assay (Figure 1).
These discrepancies may be due to differences in enzyme
concentration. For example, a concentration of ERK2 400-
fold higher than used here was reported to phosphorylate
GABPA [30]. These differences highlight the utility of
comparing all members of the family at the same time,
and in the same conditions.
The number of PX(SP/TP) motifs correlated with tar-
geting by all MAPKs, and particular D and DEF domain
sequences correlated with specificity for p38 and ERK.
However, these sequences alone could not entirely pre-
dict our findings. This is likely because of the role of
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docking sequence and the target residues. In the case of
ETS1 and ETS2, for example, the structure of the
pointed domain can mediate a specific ERK2 interaction
[52], consistent with the ERK2 specificity we observed in
Figure 1.
Our survey discovered ERK phosphorylation of S215
in ERG, and a specific antibody confirmed that this
phosphorylation event occurs in vivo (Figure 3). We
demonstrated that this phosphorylation event was re-
quired for ERG to promote prostate cell migration. ERG
is normally expressed in hematopoietic and endothelial
cells [4], but is aberrantly expressed in about one-half of
prostate cancers due to a chromosomal rearrangement
[14]. An early study indicated that ERG is heavily phos-
phorylated in myeloid cells, but these sites have not been
characterized [53]. S215 phosphorylation has been ob-
served by mass spectrometry of ERG immunoprecipi-
tated from VCAP prostate cancer cells [42], indicating
that this residue is phosphorylated in cells with the
TMPRSS2:ERG fusion. However, neither the kinase re-
sponsible, nor the importance of the phosphorylation
event was previously characterized. Our findings indicate
that ERK phosphorylates ERG through an interaction
with the DEF domain and this modification is critical for
ERG to promote prostate cell migration. This phosphor-
ylation site was found to be important for activation of
ERG target genes (Figure 4J) and for ERG chromatin oc-
cupancy (Figure 4L). However, whether this effect is due
to alteration of a protein-DNA or protein-protein con-
tact is unknown and will need to be determined in fu-
ture studies.
The higher affinity of ERK2 for ERG compared to
ETS1 correlated with the finding that ERG S215 is phos-
phorylated in cells with low levels of ERK signaling,
while ETS1 T38 is only phosphorylated in cells with high
levels of ERK signaling. It also corresponds to the find-
ing that ERG can promote cell migration in a low ERK
signaling background, but ETS1 requires a high ERK sig-
naling background (Figure 5). These data led us to
hypothesize that the difference in affinity of ERK for
ERG versus ETS1 mediates the difference in biological
function. However, there are other possible explanations.
For example, p38 and JNK can be activated by KRAS
signaling and these kinases are more specific for ETS1
than ERG (Figure 1). Therefore, these kinases could play
a role in ETS1 function when KRAS is activated. Also,
kinases downstream of ERK [54], such as RSK1 and
MSK1, would be sensitive to MEK inhibition and could
play a role in ERG or ETS1 function.
The ability of ERG to drive cell migration in a back-
ground of low, but not high RAS/ERK signaling provides
an interesting example of an oncogene that actually re-
quires low levels of an oncogenic signaling pathway. Wefound that ERG can promote an oncogenic phenotype,
cell migration, in RWPE1 cells. RWPE1 cells are grown
in media containing recombinant epidermal growth fac-
tor (EGF), which activates RAS/ERK signaling, but be-
cause the RAS/ERK pathway is intact, negative feedback
loops can keep ERK activity low [55]. In a tumor, similar,
low level ERK activity could occur through autocrine sig-
naling, or signaling from the microenvironment. Consist-
ent with this model, increases in growth factor production
are common in prostate cancer [56], but mutations that
disrupt RAS/ERK feedback and lead to very high ERK ac-
tivity are rare [57]. Further supporting this model, we have
shown that these rare activating mutations in RAS or RAF
are mutually exclusive with ERG gene rearrangements in
prostate tumors [16]. As the TMPRSS2-ERG fusion is the
most common genomic alteration in prostate cancer, and
cell migration is a key component of metastasis, the high-
affinity ERK2/ERG interaction represents a potential tar-
get for small molecule inhibition during prostate cancer
treatment.
Conclusions
Here we characterize the MAPK specificity across the
ETS family of transcription factors. Phosphorylation by
all three MAPKs tested correlated with the number of
PX(TP/SP) motifs, while p38α specificity correlated with
LRL motifs and ERK2 specificity with FXFP motifs. A
novel ERK2 phosphorylation site was identified in ERG.
Phosphorylation of this site via a high affinity interaction
with ERK2 was necessary for ERG function in prostate
cells and indicates that low level RAS/ERK signaling
may be required for ERG to drive prostate cancer.
Materials and methods
Cloning and protein purification
SPIB, ETV7, ELF3 (25728) and ELK1 (27156) clones
were obtained from Addgene or were gifts. ETV2
mRNA-ORF clone was from GeneCopoeia (EX-H1877-
M02), and ETV3L from Origene (RC22031). All other
ETS clones were reverse transcribed (RT-PCR) from
mRNA isolated from cell lines or tissues with high ex-
pression [4]. ETS open reading frames were cloned into
pET28a (Novagen) using oligonucleotides in (Additional
file 1: Table S1) and sequence verified. 6X His-tagged
proteins were induced in BL21 pRIL with 1 mM IPTG
at 37°C for 2 h. Cells were pelleted and lysed by sonic-
ation in extraction buffer (50 mM Tris, pH 7.9, 1 mM
EDTA, 1 M KCl, 1 mM DTT), and centrifuged. Inclu-
sion bodies were washed with extraction buffer, and sol-
ubilized in urea-lysis buffer (10 mM Tris, pH 7.9,
750 mM NaCl, 5 M urea, 0.1% Triton-x-100, 20 mM
imidazole) by sonication. Soluble fraction was incubated
with Ni-NTA agarose resin (Qiagen) and rotated over-
night at 4°C, washed 6 times with urea-lysis buffer and
Selvaraj et al. Cell Communication and Signaling  (2015) 13:12 Page 12 of 14eluted with urea-lysis buffer with 750 mM imidazole.
Protein was refolded by dialysis into TGEK200 (10 mM
Tris, pH7.9, 0.5 mM EDTA, 200 mM KCl, 1 mM DTT
and 10% glycerol). Concentration was calculated by
comparison to BSA standards on coomassie SDS-PAGE
gels. DNA binding activity was verified by EMSA using
the sequence: 5′ GCCACGGCCCAGGAAGTGACTCA
CCCACCCTGATG as previously described [5]. ERK2
enzyme was co-expressed with constitutively active MEK
to create pERK2, and purified from bacteria as described
[52]. JNK1 and P38α were from SignalChem.
Phosphorylation of ETS proteins
Kinase reactions were performed as described previously
[10] with some modifications. In brief, kinase reactions
were 30 min at 30°C in 20 μl of buffer containing 5 nM
kinase, 1.5 μM ETS protein, 25 mM Tris pH7.9, 1 mM
Dithiothreitol (DTT), 10 mM Magnesium Acetate,
2 mM ATP, 12 mM β- glycerophosphate, 0.5 mM
Na3VO4, 5% glycerol, 87.5 mM KCl, and 8 μCi of 3 Ci/
μmole γ-32P ATP. The kinase assays shown in the left
panels of Figure 2C also included 0.5 mg/ml bovine
serum albumin (BSA). Reactions were stopped by the
addition of 4% SDS and electrophoresed on a 12.5%
SDS-Poly acrylamide gel. Gels were stained with coo-
massie blue and radioactivity was detected by Phosphor-
Imaging (Amersham Biosciences Typhoon 9210) and
quantified using ImageQuant TL. Density of coomassie
stain was measured using ImageJ 1.48v.
Cell culture and transwell migration assays
RWPE1 and RWPE2 cell lines were cultured in
Keratinocyte SFM (Invitrogen) and 1% Penicillin/
Streptomycin (100X solution – Mediatech-Cellgro). ETS
proteins with N-terminal 3xFlag tags were stably
expressed in RWPE1 or RWPE2 cells via retrovirus as
described previously [15]. Transwell migration assays
were done as described previously [15]. In brief, 5×104
cells were introduced to the transwell (8 μM pore size;
BD Bioscience) and incubated for 60 h. Migrated cells
are reported as the mean of at least three biological rep-
licates with two technical replicates each.
Measuring RNA, protein immunoblotting, and ChIP
RNA levels were measured by quantitative RT-PCR as
described previously [15] using primers in (Additional
file 1: Table S1). Total Protein extract from equal num-
ber of cells were separated on 10% SDS-PAGE gels and
immunoblotted by standard procedures. ERK (sc-94),
Phospho ERK (sc-7383), ETS1 (sc-350) antibodies were
from Santa Cruz Biotechnology. Tubulin (T9026) and Flag
(F1894) antibodies were from Sigma. Phospho- (T38)
ETS1 (ab59179) was from Abcam. ERG (9FY) antibody
was from Biocare Medical. Phospho-specific antibody forERG S215 (pERG) was produced by Pierce Custom Ser-
vices, using the phosphorylated peptide DKALQN(pS)
PRLMHAR. ChIP from RWPE1 cells was performed as
previously described [15] using an ERG antibody (Biocare
Medical, CM421A). ChIP enrichment was assessed using
quantitative PCR and standard curves to measure copy
number of the locus of interest and two negative control
loci. Primer sequences are included in (Additional file 1:
Table S1).Inhibitor treatments and immunoprecipitation
Prior to immunoprecipitation, cells were treated for
6 hours with the following inhibitors: MEK1/2 (10 μM,
U0126, Cell Signaling), JNK (50 μM, SP600125, Cell Sig-
naling), P38 kinase (10 μM, SB203580, Cell Signaling),
AKT (20 μM, AKT inhibitor VIII, Santa Cruz Biotechnol-
ogy), PKA (40 μM, H-89 Dihydrochloride, Cell Signaling),
PI3Kinase (20 μM, LY294002, Cell Signaling), FRAP/
mTOR (40 nM, Rapamycin), or DMSO,and cells were
washed twice with ice cold 1X PBS and solubilized in
RIPA buffer (50 mM Tris–HCl, pH7.4, 150 mM NaCl,
1 mM EDTA, 1% NP-40, 1% Sodium Deoxycholic acid,
0.1% SDS, 50 mM β- glycerophosphate, 10 mM NaF,
0.5 mM DTT). Equal concentration of protein extracts
were added to the anti Flag M2 magnetic beads (Sigma)
and rotated overnight. Beads were washed 3 times with
1 M RIPA buffer and immunoblotted.Microscale thermophoresis (MST)
MST analysis used a NanoTemper Monolith NT.115
(NanoTemper Technologies) as described [58]. Briefly,
purified ERK was fluorescently labeled using an amine
reactive L001 Monolith Protein Labeling Kit RED-NHS
(NanoTemper Technologies). 200 nM ERK2 was incu-
bated for 30 minutes at room temperature in the dark
with different concentrations of purified ETS1 or ERG
protein. The samples were loaded into standard glass ca-
pillaries (Monolith NT capillaries, NanoTemper Tech-
nologies) and thermophoresis analysis was performed
(LED 80%, IR laser 80%). Dissociation constants were
calculated using NanoTemper 1.2.206 analysis program.Additional files
Additional file 1: Table S1. Cloned sequences and primers used.
Additional file 2: Figure S1. The DNA binding activity of the purified
His-tagged ETS proteins.
Additional file 3: Figure S2. Coomassie staining of in vitro kinase assay
gels.
Additional file 4: Table S2. D and DEF domains in ETS proteins.Competing interests
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